ONCOLYTICS BIOTECH INC 8-K

What Happened
On April 27, 2026, Oncolytics Biotech, Inc. (ONCY) filed a Form 8-K (Item 8.01) and issued a press release stating it has aligned with the U.S. Food and Drug Administration on plans for a controlled, randomized pivotal study in squamous cell carcinoma of the anal canal. The press release is attached to the filing as Exhibit 99.1.

Key Details

• Filing date: April 27, 2026 (Form 8-K, Item 8.01 and Item 9.01).
• Regulatory milestone: Company reported alignment with the FDA on the design/plan for a controlled randomized pivotal study in squamous cell carcinoma of the anal canal.
• Disclosure: Press release included as Exhibit 99.1 to the 8-K.
• Administrative: 8-K signed by Kirk Look, Chief Financial Officer.

Why It Matters
This announcement represents a regulatory milestone: alignment with the FDA on a pivotal study design reduces uncertainty about trial requirements and clarifies the path the company intends to pursue for clinical development in this indication. For investors, the update is material because it signals progress toward initiating a pivotal trial that could be central to any future approval strategy for Oncolytics’ therapy in anal canal squamous cell carcinoma. The filing itself contains no new financial results.